Company Encyclopedia
View More
name
Replimune
REPL.US
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells.
1.946 T
REPL.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Replimune CEO Sushil Patel Reports Disposal of Common Shares

    Replimune CEO Sushil Patel has reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This news is generated by AI and is not financial advice.

    Reuters·
    US
    REPL
    +2.03%
    Reuters·
    US
    REPL
    +2.03%

    Artisan Partners Limited Partnership Trims Holdings in Replimune Group, Inc. $REPL

    Artisan Partners Limited Partnership reduced its stake in Replimune Group, Inc. by 9.5% in Q2, owning 511,371 shares worth $4.75 million. Replimune's stock opened at $9.20, with a market cap of $721.65 million. Analysts have mixed ratings, with a consensus of 'Moderate Buy' and a price target of $9.75. Insider sales were also reported.

    Market Beat·
    US
    REPL
    +2.03%
    US
    APAM
    -0.21%
    Market Beat·
    US
    REPL
    +2.03%
    US
    APAM
    -0.21%

    Replimune Group shares are trading higher after the company announced it presented biomarker data and updated clinical data from the IGNYTE clinical trial of RP1 plus nivolumab.

    benzinga_article·
    US
    REPL
    +2.03%
    benzinga_article·
    US
    REPL
    +2.03%

    Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer ( SITC 2025 )

    Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade ...

    GlobeNewswire·
    US
    REPL
    +2.03%
    GlobeNewswire·
    US
    REPL
    +2.03%

    Replimune Group Inc. releases IGNYTE trial data on RP1 plus nivolumab in anti-PD-1-failed melanoma

    Replimune Group Inc. has released updated clinical data from the IGNYTE trial, which evaluates the combination of RP1 and nivolumab in patients with melanoma who have failed anti-PD-1 therapy. The document highlights mechanisms of resistance to immune checkpoint blockade and insights into the tumor microenvironment, suggesting potential for renewed sensitivity to anti-PD-1 treatment. The full document is available via a provided link.

    Reuters·
    US
    REPL
    +2.03%
    Reuters·
    US
    REPL
    +2.03%
    © 2025 Longbridge｜Disclaimer